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Correspondence
Acute COVID-19 induced fulminant systemic
vascular thrombosis: A novel entity
To the editor,
Coronavirus disease 2019 (COVID-19) has been implicated in
the etiology of deep venous thrombosis, stroke and pulmonary
embolism [1–3]. Here, we invoke a new variant of coagulopathy,
acute COVID-19 induced fulminant systemic vascular thrombosis
(ACoFSVT) characterized by a rapid, widespread, massive periph-
eral arteriovenous coagulopathy.
A 74-year-old male with a past medical history of Diabetes Mel-
litus (DM) presented with lethargy and hypoxia since one day
prior. Additional history was limited, given his altered mental
status.
In the emergency department (ED), he was febrile (39.1 celsius),
tachycardic and tachypneic (respiratory rate 40 breaths per min-
ute). His blood pressure was 75/50 mmHg. Arterial oxygen satura-
tion was 44% requiring emergent intubation and mechanical
ventilation. Electrocardiogram (EKG) demonstrated sinus tachy-
cardia and a chest X-ray revealed bilateral interstitial infiltrates.
He received vigorous intravenous fluid resuscitation followed by
inotropic support with norepinephrine infusion. Given concerns
for sepsis, broad-spectrum antibiotics were also initiated.
Initial laboratory investigation revealed prerenal azotemia
(blood urea nitrogen 121 mEq/L, creatinine 3.59 mg/dl), hyperna-
tremia (154 mEq/L), hyperkalemia (6.4 mEq/dL), and rhabdomyol-
ysis Creatine Kinase (4673 U/L). His serum d-dimer level, C-
reactive protein (CRP), and lactate dehydrogenase (LDH) were ele-
vated at 69,000 ng/mL, 199 mg/dL and 910U/L, respectively (Fig. 1).
The following day, a real-time polymerase chain reaction for sev-
ere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
returned positive. He was initially treated with hydroxychloro-
quine but this was later discontinued due to QT prolongation
and short bursts of nonsustained ventricular tachycardia. Inter-
leukin-6 (IL-6) inhibitors could not be utilized given his raised
aminotransferase levels (450 IU/L), alanine aminotransferase
(540 IU/L) and thrombocytopenia. The latter also precluded us
from starting empiric therapeutic anticoagulation.
On day-2, he developed bilateral lower extremity edema,
prompting venous imaging of the lower extremities. Doppler ultra-
sound (DUS) revealed widespread occlusive thrombosis in the
right femoral and bilateral popliteal veins. DUS of the upper
extremities also revealed occlusive thrombi in the right cephalic
and left basilic vein. He was immediately started on therapeutic
intravenous unfractionated heparin.
Two days later, he developed skin mottling and discoloration on
the bilateral lower extremities and peripheral pulses could not be
elicited. An arterial DUS of the lower extremities demonstrated
massive occlusive thrombi in the bilateral common femoral, pro-
funda femoris, superficial femoral, posterior tibial, peroneal and
posterior tibial arteries. (Fig. 2) Given the extensive clot burden,
anticoagulant was switched to argatroban, fearing heparin failure
and considering the remote possibility of Heparin-induced throm-
bocytopenia. An extensive hypercoagulability workup comprising
heparin-induced thrombocytopenia antibody testing, lupus antico-
agulant (DRVVT), anticardiolipin antibody and beta-2-glycoprotein
were negative. The rapidly progressing ischemia on anticoagulants,
and bilateral lower extremities involvement was concerning for
non-viable limbs.
After introspection with hematology, vascular surgery, and the
family, it was decided that he would be a poor candidate for both
for catheter-directed thrombolysis or vascular bypass surgery. Sur-
gical intervention with emergent bilateral femoral endarterectomy
followed by thrombectomy were attempted, however he eventu-
ally needed above knee lower extremity amputations. The hospital
course was further complicated by persistent fevers, rhabdomyol-
ysis, diffuse coagulopathy and a urinary tract infection in conjunc-
tion with COVID-19. Given his clinical deterioration, his family
eventually opted to proceed with comfort directed care and trans-
fer to a hospice facility.
The novel COVID-19 is a generation-defining global pandemic;
the scale, scope and pace of which is unprecedented. The statistics
to date are staggering. As of April 30, 2020, more than 3million
confirmed cases from over 180 countries and more than 233,000
deaths had been documented worldwide. The estimated case bur-
den in the US alone is expected to be 2–3 million. Given this, the
mounting toll of COVID-19 related systemic and vascular compli-
cations requiring critical interventions could be daunting.
SARS-CoV-2 infection can elicit an intense inflammatory
response by recruiting multiple cytokines and chemokines (IL-6,
tumor necrosis factors), leading not only to direct endothelial
injury but also to diffuse vascular inflammation. The Endothelial
dysfunction seems to be mediated via viral infection of the
endothelial cell. Also the impaired systemic microcirculatory func-
tioning, vasoconstriction, stasis of blood flow during immobiliza-
tion, changes in circulating prothrombotic factors during active
infection may all potentiate this procoagulant state [2,4]. COVID-
19 induced hypoxia, immobilization and reactive thrombocytosis,
can also precipitate multivessel thrombosis [5]. Contemporary
studies have shown that the degree of thrombosis may correlate
with titers of coagulation biomarkers. Elevated levels of d-dimer
have been shown to directly correlate with higher Sequential
Organ Failure Assessment (SOFA) scores and worse clinical out-
comes [6]. A multivariable regression has also shown increased
odds of poor prognostic factors associated with d-dimer level
greater than 1 lg/mL (1842, 264–12855; p = 00033) [4].
In our case, irrespective of the endothelial injury, the collision
of COVID-19 induced direct vascular thrombosis, inherent to the
disease-specific hypercoagulable state, and possible vasculopathy,
due to long-standing diabetes triggered vascular occlusion. The
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Fig. 1. In-hospital course, vitals and lab findings (yellow indicates on presser support, highlighted areas are abnormal values, MV: Mechanical Ventilation, NC: Nasal
Cannula). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2. (A) Left common femoral and (B) profunda femoris artery with a large occluding thrombus in the lumen and negative biphasic flow on Doppler ultrasound. (C)
Biphasic flow waveform demonstrating absence of blood flow below proximal part of the femoral artery.
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rise in d-dimer levels tracked with inflammatory biomarkers (CRP),
reflecting both coagulopathy and vascular inflammation, a cause
for acute COVID-19 related fulminant systemic vascular thrombo-
sis (ACoFSVT). While a constellation of multiple mechanisms
incited ACoFSVT, the resulting rhabdomyolysis, electrolyte distur-
bance and kidney failure further complicated the clinical course of
our patient.
Although pathologically unproven, the dramatic cratering clin-
ical trajectory of our patient despite being on therapeutic heparin
also suggests that ACoFSVT severely disrupts normal homeostatic
mechanisms, exhausting anticoagulant factors and leading to
unopposed clotting pathway activation. This, especially in the set-
ting of possible pre-existing endothelial dysfunction due to DM,
precipitated widespread thrombosis [6]. One can also argue that
lack of definitive treatment for COVID-19 and possible delay in
the administration of heparin infusion due to thrombocytopenia
on presentation might have contributed to the development of
ACoFSVT. Regardless, it is imperative to identify early clinical risk
factors such as baseline medical conditions that predispose to vas-
culopathy, significant elevated inflammatory markers and in par-
ticular high levels of d-dimer, and adopt an individualized
approach to initiation of early therapeutic anticoagulation in these
patients.
While remarkable efforts to unravel further management of
acute COVID-19 related thrombotic complications are ongoing,
we advocate for early recognition and timely anticoagulation in
patients with high-risk features suggestive of ACoFSVT.
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